BC Week In Review | Oct 6, 2017
Company News

NIAID exercises option to develop MGD014 from MacroGenics

In early September, MacroGenics Inc. (NASDAQ:MGNX) said NIH's National Institute of Allergy and Infectious Disease (NIAID) exercised the first of two options under a September 2015 deal and will provide up to $10.8 million in...
BC Innovations | Oct 22, 2015
Distillery Therapeutics

Therapeutics: CD3; HIV env

Infectious disease INDICATION: HIV / AIDS In vitro studies suggest a dual-affinity re-targeting (DART) antibody against CD3 and HIV env could help treat HIV infection. A DART consisting of two disulfide-linked polypeptide chains corresponding to...
Items per page:
1 - 2 of 2